Biomerica (BMRA) Reports Q2 Loss of $1.32 Million, Revenue Down 26.2%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: NASDAQ.COM
- Widening Losses: Biomerica reported a net loss of $1.32 million in Q2, a 39.5% increase from last year's loss of $0.95 million, indicating greater pressure on the company's profitability.
- Revenue Decline: The company's revenue fell to $1.21 million, down 26.2% from $1.64 million last year, reflecting weak market demand and sales challenges that could impact future liquidity.
- Performance Comparison: The loss per share widened from $0.09 to $0.12 compared to the same period last year, suggesting that efforts to control costs and boost revenue have not yielded expected results.
- Market Outlook: With both revenue and profitability declining, Biomerica may need to reassess its market strategy to navigate the current economic environment and competitive pressures in the industry.
Analyst Views on BMRA
About BMRA
Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are utilized in the analysis of blood, urine, nasal, or fecal samples for the diagnosis of various diseases, food intolerances, and other medical conditions. Its range of medical diagnostic products is sold primarily in two markets: clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter sales. It is focused on research and development efforts and is its patented diagnostic-guided therapy (DGT) product, developed on the in Foods technology platform. Its inFoods IBS product, uses a simple blood test to identify patient-specific foods that, when eliminated, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping, and constipation. Its hp+detect, a new diagnostic test for detecting Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
